Vaxxinity (VAXX) Competitors $0.01 +0.01 (+4,900.00%) As of 04/17/2025 09:43 AM Eastern Add Compare Share Share Competitors Stock AnalysisChartCompetitorsInsider TradesSEC FilingsTrendsBuy This Stock VAXX vs. NAVB, HEPA, SMFL, SCPS, EVLO, CMRA, GNCAQ, GNCA, ARDS, and CALAShould you be buying Vaxxinity stock or one of its competitors? The main competitors of Vaxxinity include Navidea Biopharmaceuticals (NAVB), Hepion Pharmaceuticals (HEPA), Smart for Life (SMFL), Scopus BioPharma (SCPS), Evelo Biosciences (EVLO), Comera Life Sciences (CMRA), Genocea Biosciences (GNCAQ), Genocea Biosciences (GNCA), Aridis Pharmaceuticals (ARDS), and Calithera Biosciences (CALA). These companies are all part of the "pharmaceutical products" industry. Vaxxinity vs. Navidea Biopharmaceuticals Hepion Pharmaceuticals Smart for Life Scopus BioPharma Evelo Biosciences Comera Life Sciences Genocea Biosciences Genocea Biosciences Aridis Pharmaceuticals Calithera Biosciences Vaxxinity (NASDAQ:VAXX) and Navidea Biopharmaceuticals (NYSE:NAVB) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their dividends, profitability, analyst recommendations, risk, valuation, institutional ownership, community ranking, earnings and media sentiment. Which has preferable valuation & earnings, VAXX or NAVB? Navidea Biopharmaceuticals has higher revenue and earnings than Vaxxinity. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioVaxxinityN/AN/A-$56.93M-$0.45-0.02Navidea Biopharmaceuticals$8.13K7.39-$15.18MN/AN/A Does the media favor VAXX or NAVB? In the previous week, Vaxxinity's average media sentiment score of 0.00 equaled Navidea Biopharmaceuticals'average media sentiment score. Company Overall Sentiment Vaxxinity Neutral Navidea Biopharmaceuticals Neutral Which has more risk and volatility, VAXX or NAVB? Vaxxinity has a beta of -19.23, meaning that its stock price is 2,023% less volatile than the S&P 500. Comparatively, Navidea Biopharmaceuticals has a beta of 2.04, meaning that its stock price is 104% more volatile than the S&P 500. Does the MarketBeat Community believe in VAXX or NAVB? Vaxxinity received 5 more outperform votes than Navidea Biopharmaceuticals when rated by MarketBeat users. Likewise, 38.46% of users gave Vaxxinity an outperform vote while only 0.00% of users gave Navidea Biopharmaceuticals an outperform vote. CompanyUnderperformOutperformVaxxinityOutperform Votes538.46% Underperform Votes861.54% Navidea BiopharmaceuticalsOutperform VotesNo VotesUnderperform Votes83100.00% Do insiders and institutionals believe in VAXX or NAVB? 82.9% of Vaxxinity shares are owned by institutional investors. Comparatively, 0.0% of Navidea Biopharmaceuticals shares are owned by institutional investors. 64.1% of Vaxxinity shares are owned by company insiders. Comparatively, 43.7% of Navidea Biopharmaceuticals shares are owned by company insiders. Strong institutional ownership is an indication that hedge funds, large money managers and endowments believe a stock is poised for long-term growth. Is VAXX or NAVB more profitable? Company Net Margins Return on Equity Return on Assets VaxxinityN/A N/A N/A Navidea Biopharmaceuticals N/A N/A N/A SummaryVaxxinity beats Navidea Biopharmaceuticals on 4 of the 7 factors compared between the two stocks. Get Vaxxinity News Delivered to You Automatically Sign up to receive the latest news and ratings for VAXX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart VAXX vs. The Competition Export to ExcelMetricVaxxinityPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.27M$6.44B$5.30B$7.35BDividend YieldN/A3.23%5.12%4.31%P/E Ratio-0.026.8821.7717.77Price / SalesN/A231.02379.4097.65Price / CashN/A65.6738.2634.64Price / Book0.095.916.443.98Net Income-$56.93M$142.72M$3.21B$247.44M7 Day PerformanceN/A4.33%2.82%1.82%1 Month PerformanceN/A-12.80%-8.67%-6.98%1 Year PerformanceN/A-9.71%11.38%1.49% Vaxxinity Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)VAXXVaxxinityN/A$0.01+4,900.0%N/A-97.6%$1.27MN/A-0.0290Upcoming EarningsGap UpNAVBNavidea BiopharmaceuticalsN/A$0.00+20.0%N/A-98.6%$60,000.00$8,126.000.0010Analyst ForecastGap UpHEPAHepion Pharmaceuticals0.3211 of 5 stars$0.41-6.8%N/A-99.7%$57,000.00N/A-0.0920Short Interest ↑News CoverageGap DownHigh Trading VolumeSMFLSmart for LifeN/A$0.00+38.5%N/A-100.0%$26,000.00$11.11M0.00110SCPSScopus BioPharmaN/A$0.00flatN/AN/A$13,000.00N/A0.009High Trading VolumeEVLOEvelo BiosciencesN/A$0.00flatN/A-98.9%$9,000.00N/A0.00120Upcoming EarningsOptions VolumeNews CoverageCMRAComera Life SciencesN/A$0.00flatN/AN/A$6,000.00$1.00M0.002GNCAQGenocea BiosciencesN/AN/AN/AN/A$6,000.00N/A0.0070GNCAGenocea BiosciencesN/AN/AN/AN/A$6,000.00$1.91M0.0070ARDSAridis PharmaceuticalsN/AN/AN/AN/A$5,000.00$3.09M0.0030CALACalithera BiosciencesN/A$0.00+66.7%N/A-87.5%$5,000.00N/A0.0060Analyst ForecastNews Coverage Related Companies and Tools Related Companies Navidea Biopharmaceuticals Competitors Hepion Pharmaceuticals Competitors Smart for Life Competitors Scopus BioPharma Competitors Evelo Biosciences Competitors Comera Life Sciences Competitors Genocea Biosciences Competitors Genocea Biosciences Competitors Aridis Pharmaceuticals Competitors Calithera Biosciences Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:VAXX) was last updated on 4/18/2025 by MarketBeat.com Staff From Our PartnersCrypto’s crashing…but we’re still profitingMost traders are panicking right now. Bitcoin’s dropping. Altcoins are bleeding. The stock market’s a mess....Crypto Swap Profits | SponsoredHow War with China Could Start in 128 DaysThe clock is ticking. Those who aren't prepared could lose everything. I've identified 43 investments we...Behind the Markets | SponsoredMy prediction is coming trueWe've developed a surprisingly effective way to see which stocks could double during massive shake-ups, by usi...InvestorPlace | SponsoredRead before the next tariff announcementLarry Benedict, the acclaimed "Market Wizard," is calling an emergency briefing now... The same Larry who –...Brownstone Research | Sponsored🥾⛏️👷♂️ What I Learned From Numerous Mine Visits...Twenty years ago, I made a decision that changed my life. Instead of sitting behind a desk analyzing mining...Golden Portfolio | SponsoredNow I look stupid. Real stupid... I thought what happened 25 years ago was a once- in-a-lifetime event… but how wrong I was. Because here we...Porter & Company | SponsoredWhy Elon put $51 million into thisWhy Elon Musk Just Invested $51 Million Into Brand New “Miracle Metal” Developed by MIT ScientistsTrue Market Insiders | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Vaxxinity, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Vaxxinity With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy VAXX Stock Free VAXX Stock Alerts